Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 25, 2021 / 01:00PM GMT
Release Date Price: €69.3 (+0.70%)
Marc Harold Goodman
SVB Leerink LLC, Research Division - MD of Neuroscience & Senior Research Analyst

All right. Good morning, everybody. Welcome back to day 4 of the SVB Leerink Healthcare Conference. I'm Marc Goodman, one of the biopharma analysts. And we are happy to start this morning off with Sage Therapeutics. Appreciate you guys joining us. We have Steve Kanes, who's the Chief Medical Officer, been at the company, I believe, about 8 years; and Mike Cloonan, who's the Chief Operating Officer, and Mike joined the company about 4 years ago. And so thank you both for joining us.

And I think, Mike, you're going to make some opening comments before we jump into a Q&A session.

Michael Cloonan
Sage Therapeutics, Inc. - COO

Yes. Thanks, Marc, and good morning, everyone. Thanks for having us today. Thanks for jumping on the call and listening in, and I'll be quick with -- I know people want to get into the questions. But just to set the stage and where Sage is at. We're really excited about where we're at. You know a lot about Sage, but our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot